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A novel stepwise integrative 
analysis pipeline reveals distinct 
microbiota‑host interactions 
and link to symptoms in irritable 
bowel syndrome
Annikka Polster1*, Lena Öhman1,2, Julien Tap3, Muriel Derrien3, Boris Le Nevé3, 
Johanna Sundin1,2, Hans Törnblom1, Marija Cvijovic4,6 & Magnus Simrén1,5,6
Although incompletely understood, microbiota‑host interactions are assumed to be altered in 
irritable bowel syndrome (IBS). We, therefore, aimed to develop a novel analysis pipeline tailored for 
the integrative analysis of microbiota‑host interactions and association to symptoms and prove its 
utility in a pilot cohort. A multilayer stepwise integrative analysis pipeline was developed to visualize 
complex variable associations. Application of the pipeline was demonstrated on a dataset of IBS 
patients and healthy controls (HC), using the R software package to analyze colonic host mRNA and 
mucosal microbiota (16S rRNA gene sequencing), as well as gastrointestinal (GI) and psychological 
symptoms. In total, 42 IBS patients (57% female, mean age 33.6 (range 18–58)) and 20 HC (60% 
female, mean age 26.8 (range 23–41)) were included. Only in IBS patients, mRNA expression of 
Toll‑like receptor 4 and genes associated with barrier function (PAR2, OCLN, TJP1) intercorrelated 
closely, suggesting potential functional relationships. This host genes‑based “permeability cluster” 
was associated to mucosa‑adjacent Chlamydiae and Lentisphaerae, and furthermore associated to 
satiety as well as to anxiety, depression and fatigue. In both IBS patients and HC, chromogranins, 
secretogranins and TLRs clustered together. In IBS patients, this host genes‑based “immune‑
enteroendocrine cluster” was associated to specific members of Firmicutes, and to depression and 
fatigue, whereas in HC no significant association to microbiota was identified. We have developed 
a stepwise integrative analysis pipeline that allowed identification of unique host‑microbiota 
intercorrelation patterns and association to symptoms in IBS patients. This analysis pipeline may aid 
in advancing the understanding of complex variable associations in health and disease.
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IBS  Irritable bowel syndrome
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IBS-C  IBS with constipation
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IBS-M  IBS with mixed loose and hard stools
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IL  Interleukin
TJP  Tight junction protein
TLR  Toll-like receptor
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TNF  Tumor necrosis factor
OCLN  Occludin
TPH 1  Tryptophan hydroxylase 1






NOX  NAD(P)H oxidase
FFAR  Free fatty acid receptor
SLC  Solute carrier
Irritable Bowel Syndrome (IBS) is the most common functional bowel disorder, affecting around 10% of the 
general  population1–4. It is characterized by chronic and recurrent abdominal pain in combination with altered 
bowel  habits1,2. IBS strongly reduces quality of life and social  function5–7 and leads to frequent work  absenteeism7, 
resulting in a significant personal and societal economic  loss7,8. To this day the etiology and the underlying patho-
physiological mechanisms are incompletely understood, and treatment options remain sparse and  suboptimal9. 
To improve this situation there is an ongoing effort to better understand the complex pathophysiology, in hopes 
of identifying biomarkers which can be utilized to improve diagnosis and predict treatment  response10.
A low-grade activation of the immune system seems to be present in at least a subset of IBS  patients11–15. This 
has been suggested to be of relevance for symptom generation by influencing the bidirectional communication 
between gut and brain (gut-brain axis) and affecting gastrointestinal (GI) sensitivity and motility, and thus 
leading to IBS  symptoms16.
The gut microbiota ecosystem and its role in IBS symptom generation has been subject to extensive research 
in the last years, with findings in patients suggesting an altered microbiota  composition17–19, or a potential over-
reaction to gut microorganisms or their  metabolites20, as well as an influence of microbiota on the gut-brain 
 axis21,22, thus contributing to both GI and psychological  symptoms23–26.
Intestinal low-grade inflammation and microbiota alterations are hypothesized to be  connected16, opening 
the question as to how exactly this host-microbiota interaction is orchestrated in the gut and how this interaction 
may contribute to symptom generation in IBS patients. An interaction between gut microbiota and the immune 
system takes place at the mucosal border, where the mucosal tissue presents a semipermeable barrier between 
the body and the intraluminal gut environment. Given the difficulties of culturing many of the gut microbial 
species, the detailed understanding of the functional interaction between host and gut microbiota is currently 
very limited. In silico tools that simplify the preselection of mediators with potential disease-related relevance 
would greatly facilitate the design and conduction of more detailed experimental analyses to elucidate how this 
interaction is orchestrated.
We hypothesize that the functionally related variables of this biological system exhibit an interdependence, 
which can be approximated by the correlations between these variables. Potentially, an integrative analysis 
pipeline as an exploratory method to simultaneously analyze all variables of multi-level datasets and visualize 
complex variable associations in order to extract relevant information, may identify which mediators involved to 
be most relevant in this interaction. The aim of this study was therefore to develop a stepwise integrative network 
analysis pipeline tailored to comprehensively analyze host-microbiota interactions and the association to key 
IBS symptoms. Further, we exemplify how our approach is useful for understanding relationships between gut 
microbiota, host barrier function and symptoms.
Material and methods
Study cohort and biopsy collection. A cohort of well-characterized adult patients (≥ 18 years) fulfilling 
the Rome III criteria for  IBS2, were recruited at the gastroenterology outpatient clinic at Sahlgrenska Univer-
sity Hospital in Gothenburg, Sweden. The diagnosis of IBS was based on the clinical presentation with normal 
results on a limited number of investigations and tests as deemed appropriate by an experienced gastroenter-
ologist (MS or HT). The majority of patients were referred from primary care after having already performed 
sufficient investigations to rule out other diagnoses. Exclusion criteria included: abnormal results on standard 
screening laboratory tests, other GI diseases or severe psychiatric or systemic diseases. Healthy controls were 
recruited through advertisement and had no history of Gl or other acute or chronic diseases and no current 
GI symptoms (assessed for the previous seven days). For all participants any history of drug or alcohol abuse 
and the inability to reliably respond to questionnaires in Swedish lead to exclusion. Any active infection (such 
as respiratory tract infections) also lead to exclusion, but no screening for recent infections was performed. All 
study participants refrained from any medication known to affect the nervous system or the GI tract during the 
course of this study. The use of probiotics or antibiotics was not allowed during the study period or within one 
month before inclusion. Informed consent was obtained for all participants in the study. They gave their writ-
ten consent to participate after verbal and written information, all methods were performed in accordance with 
relevant guidelines and regulations and the study protocol was approved by the Regional Ethical Review Board 
in Gothenburg prior to the start of patient inclusion (approval number 731–09). Patients and HC were recruited 
as part of an extensive pathophysiological research program which included phenotyping of GI sensorimotor 
function, symptom profiles and mucosal functioning. Mucosal biopsies were obtained during a sigmoidoscopy 
(performed without prior bowel preparation) from 25–35 cm proximal of the anal sphincter using standard 
biopsy forceps. The biopsy specimens were taken 25–35 cm proximal of the anus during an unprepared sigmoi-
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doscopy. Once collected, biopsy specimens were placed immediately in liquid nitrogen and stored at − 80 °C 
until further analysis. To verify the absence of active inflammation a routine histopathology assessment of biopsy 
specimens was conducted.
Symptom assessment and IBS subtypes. To score GI symptom severity, we utilized the Gastrointes-
tinal Symptom Rating Scale (GSRS-IBS)27, a validated 13-item questionnaire commonly used to assess the GI 
symptoms typically present in IBS. This questionnaire scores symptoms on a 7-point Likert scale from 1 = “No 
discomfort at all” up to 7 = “Very severe discomfort”. We have used the five GSRS domain scores (‘abdominal 
pain’, ‘constipation’, ‘diarrhea’, ‘satiety’ and ‘bloating’) to represent the severity of the different major IBS symp-
toms in our patients.
Psychological symptoms were measured using the Hospital Anxiety and Depression (HAD)28 scale, the Vis-
ceral Sensitivity Index (VSI)29 and the Multidimensional Fatigue Inventory (MFI)30.
The  HAD28 measures psychological distress and was developed primarily for use in medical outpatients. It 
consists of 14 questions, each measuring severity with a 4-grade Likert scale (0–3). We have used these to calcu-
late subscales for severity of anxiety (seven items) and depression (seven items), where the severity is rated on a 
scale from 0 to 21 with increasing severity reflected by a higher score.
The  VSI29 contains 15 questions inquiring how patients respond to symptoms of the lower abdomen, and 
measures the severity of adverse responses on a 6-grade Likert scale. We have used the sum score of these items 
to measure the degree of GI-specific anxiety.
The  MFI30 uses 20 question to measure different aspects of fatigue on a scale ranging from 4 to 20, with 
increasing severity reflected by a higher score. We have used the subscore measuring general fatigue in our 
analysis.
To determine IBS subtypes (Rome III)2, patients completed a two-week stool diary using the Bristol Stool 
Form  scale31. Subtypes were based on the predominant stool consistency in concordance with the Rome III 
committee  suggestions2. The subtypes IBS-M (mixed type) and IBS-U (unsubtyped) were combined into one 
group, IBS without predominant diarrhea or constipation, IBS-nonCnonD.
Analysis of host gene expression. The following genes representing mucosal permeability, endocrine 
activity, microbial recognition and local immune-activity were assessed in the mucosal biopsies: Microbial rec-
ognition receptors (TLR 2,4,6,9; PAR2); indicators of barrier function (CLD1; MUC; OCLN; TJP1); cytokines 
(IL8; IL10; TNFα); granins (CHGA, CHGB, SCG2, SCG3); indicators of oxidative stress (DOUX2; NOX1); free 
fatty acid receptors (FFAR 2,3) and indicators of enteroendocrine function (TPH1; SLC6A4).
These markers were measured using quantitative reverse transcription PCR analysis to quantify the respec-
tive mRNA expression. To extract mRNA, the NucleoSpin RNA Kit was used according to the manufacturer’s 
protocol (Ref. 740,955.50, Macherey–Nagel, Düren, Germany): The biopsy was placed in lysis buffer and homog-
enized for two bursts lasting 2 min. Extracted mRNA was stored at − 80 °C. For quantification the mRNA was 
reverse-transcribed to cDNA using the “Master mix Reverse Transcription Kit” (Ref. 11,755,250, Life Technolo-
gies, Carlsbad, CA). This cDNA was added to 96-well plates containing lyophilized target probes and primers 
and the polymerization process was conducted using «Taqman Fast Advanced Master Mix» (Ref. 444,965, Life 
Technologies). To normalize the expression of the targeted genes sequence of interest, the average expression 
of several reference housekeeping genes (18S, POLR2A and RPLP0) was measured. The difference between the 
average expression of reference genes and that of the sequence of interest is given as Δ Ct (cycle threshold) and 
presented as  2−(Target-Reference) or  (2ΔCt). Several housekeeping genes were used in this normalization step to mini-
mize the chance of faulty normalization and to achieve high-quality inter-plate validation. Each analysis was run 
in triplicate and the triplicates averaged.
Analysis of mucosa‑adjacent microbiota. Mucosa-adjacent microbiota DNA were isolated using 
an adapted protocol based on Godon et al.32 as previously described in Tap et al.17. In short, amplification of 
hypervariable 16S rRNA regions (V5-V6) was conducted using the primers 5′-AGG ATT AGA TAC CCT GGT 
A-3′ and 5′-CRR CAC GAG CTG ACGAC-3′. Sequencing was performed using the DNA Vision SA (Charleroi, 
Belgium) on a 454 Life Sciences Genome Sequencer FLX instrument (Roche) with titanium chemistry. The 
quality filtering and trimming of raw reads as well as OTU (operational taxonomic units) clustering and taxo-
nomic assignment were performed using the LotuS v1.32 pipeline. If OTUs could not be assigned as detailed as 
genus-level, the most detailed taxonomical assignment achieved is given. Normalization for sequencing depth 
was performed by the median of ratios method, on the OTU table, as implemented in  DESeq233 in  R34 and the 
abundance of 188 bacterial genera used for further analysis. Phylum-level taxonomic assignment was used for 
the overview-models, while taxonomic assignment up to genus-level was used for detailed analyses of the inter-
correlation clusters as described in the statistical section. Phyla/genera that were screened for but showed no hits 
were removed from the network analysis plots.
Data analysis. All data analyses were performed using R (version 3.4.1—“Single Candle”)34. Univariate 
comparisons were performed using Students T-test for parametric as well as Mann–Whitney U test for non-
parametric data or Pearsons’  Chi2 test as appropriate. The network analysis in the pilot study was based on a cor-
relation matrix of Spearman correlations to account for non-parametric data. The relative correlation strength 
between each variable pair determined the placement of the nodes and thickness of the edges (the connect-
ing lines in-between), with closer approximation of nodes and thicker edges in-between reflecting a stronger 
correlation. The graphs were then created by plotting intercorrelations between all variables, which resulted 
in clustering of nodes in the cases where several variables were correlated with each other with high relative 
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correlation strength. The network visualizations were conducted using the “qgraph”-package (version 1.4.0)35. 
Levels of α = 0.05 (p < 0.05) were considered statistically significant. In the pilot analysis significance values were 
calculated uncorrected for multiple testing to favor type 1 over type 2 error given the exploratory nature of 
the analysis. Both cohorts were checked for multivariate outliers using principal component analysis (with the 
inbuilt ‘prcomp’ function in R), and strong outliers (defined as being more than 10 units outside of the 95% 
confidence interval) were removed.
For the presented pilot study, the stepwise integrative analysis was conducted in 7 steps which are visualized 
in Fig. 1:
1. Data preparation: To limit the complexity of the initial integrative analysis an initial summarizing or clus-
tering step is necessary. Given the limited knowledge of the physiological functioning of the gut microbial 
species, we here decided to use phylogenetic relatedness to summarize the bacterial genera into the respec-
tive phyla for the initial integrative analysis. As the pilot study dataset only contained a limited number of 
mucosal genes, these were not summarized here. The resulting datasets were quality checked using principal 
component analysis to test for multivariate outliers. This step was conducted with regards to the strong 
heterogeneity of the gut ecosystem as well as potential technical artifacts of the microbial and molecular 
analyses. Patients and HC were analyzed separately, and strong outliers were removed from the subsequent 
analysis if appropriate to reduce the risk for false-positive correlation results.
2. Integrative analysis on phylum level: At first all correlations between host genes and microbial phyla were 
plotted in their relative correlation strength, disregarding the statistical significance of the correlations, in 
order to create an overview plot reflecting the intercorrelation-based associations between the measures in 
the analyzed cohort. This step gives a graphical representation of interconnectedness of the variables entered 
into the model and was used to identify clusters of close intercorrelation between markers of mucosal activity 
and microbiota. Secondly, the same correlation matrix was plotted, but statistically insignificant correlations 
(p ≥ 0.05) were omitted from the plot. This step was conducted especially with regards to exploring the sta-
tistical significance of the before identified intercorrelation clusters.
Figure 1.  Overview of the steps performed for analyzing the pilot study dataset.
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3. Comparison of network characteristics between IBS patients and HC: The plots derived from step 2 were 
compared between patients and HC regarding network patterns/clusters as well as network density and dif-
ferences in network patterns highlighted.
4. Association to symptoms: Here three separate network plots were created, representing (i) associations 
between microbiota and host genes, as performed in step 2, (ii) associations between GI symptoms and (iii) 
associations between psychological symptoms. Statistically significant correlations between variables of these 
plots were then added to create the respective figures.
5. Selection of most relevant variables: Steps 3 and 4 were used to select variables that were part of patient-
specific network patterns and/or significantly correlated to symptoms.
6. Data preparation: In step 5 noteworthy phyla were selected, which were now split up again into the respec-
tive genera, to achieve a more detailed understanding of which specific genera were associated to the respec-
tive mucosal genes. Another quality check was performed as described in step 1.
7. Integrative analysis on genus level: Previously identified relevant mucosal genes and associated microbiota 
were plotted and associations tested for statistical significance.
Likewise, microbiotas associated only to clinical symptoms were plotted and associations tested for sta-
tistical significance.
Results
Development of an integrative analysis pipeline. This section presents the developed integrative 
analysis pipeline, whereas the execution of the steps in the pipeline on the dataset, and the results thereof, are 
described in the consecutive sections. A conceptual visualization of the integrative analysis pipeline is given 
in Fig. 2. Thus, variables A (for example gut microbiome) and variables B (for example host gene expression) 
are initially combined into summary-variables that are then associated to each other in an integrative analysis, 
and plotted in a network graph. The initial summarizing step is relevant to enhance the visibility of patterns in 
the network graph. This is done separately in both patients and HC, and are then compared between the two 
groups. Furthermore, the patient network is associated to variables representing the clinical phenotype, such as 
key symptoms. By comparing patients to HC and by associating to the clinical phenotype, summary-variables of 
high interest are identified. These specific summary-variables are then de-summarized to identify in detail which 
variables are directly associated.
Description of the study cohort. The gender distribution among IBS patients and HC was similar, but 
the mean age was higher in the IBS group. Most patients had moderate symptom severity as measured by the 
GSRS subscores with the median of the respective scores ranging from 2.5 (satiety) to 4.7 (bloating) (total range 
of GSRS scores 1–7), and Rome III subtypes were present to a similar extent. Details are shown in Table 1 and 
Fig. 3.
The averaged expression levels of the mucosal host genes did not differ between IBS patients and HC. How-
ever, in IBS patients significantly less OTUs were assigned to unclassified Bacteria, to Lentisphaerae and Firmi-
cutes (all p < 0.01). Expression of mucosal host genes as well as normalized microbiota OTU counts are shown 
in Supplementary Figures 1 and 2.
Figure 2.  Concept of the stepwise integrative analysis pipeline.
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Application of the integrative analysis of host‑microbiota interactions. The mucosal host-
microbiota interaction model in IBS patients and HC based on intercorrelation of all variables is visualized in 
Fig. 4. The network density, describing the number of actual connections in relation to the number of possible 
connections was higher with regards to correlation strength in the HC network, defined as density of connec-
tions where p > 0.3 (IBS = 14.8% vs. HC = 18.9%) (Fig. 4A). The IBS patients’ network however showed a higher 
density with regards to statistically significant connections, defined as density of connections where p < 0.05 
(IBS = 15.8% vs. HC = 13.0%) (Fig. 4B). Two outliers were removed in the PCA step.
All correlation coefficients of the two models are given in Supplementary Figures 2 and 3.
Uniquely in patients, a cluster of four host genes associated to barrier function and microbial recognition 
was identified, referred to as the ‘permeability cluster, which was associated to the phyla Chlamydiae and Len-
tisphaerae (Fig. 4 A and B). In both patients and HC, a cluster consisting of secretogranins and chromogranins 
as well as microbial recognition receptors was identified (six genes in IBS and seven in HC), referred to as the 
Table 1.  Demographics, Rome III subtypes and symptom severity. GSRS: gastrointestinal symptom rating 
scale. HAD: Hospital anxiety and depression scale. VSI: Visceral sensitivity index. MFI: multidimensional 




Gender female/male 24/18 12/8
Age mean (range) 33.6 (18–58) 26.8 (23–41) 0.6a
IBS-C 13 31% 0.02b
IBS-D 15 35.7%
IBS-nonCnonD 14 33.3%
Abdominal pain (GSRS) Median (IQR) 5 (3–5.5)
Constipation (GSRS) Median (IQR) 3 (1.3–4.5)
Diarrhea (GSRS) Median (IQR) 3.5 (2.5–4.8)
Bloating (GSRS) Median (IQR) 4.7 (3.3–5.3)
Satiety (GSRS) Median (IQR) 2.5 (1–3.8)
General anxiety (HAD) Median (IQR) 6 (3–10.5)
Depression (HAD) Median (IQR) 4 (1.5–6.5)
GI-specific anxiety (VSI) Median (IQR) 42 (26.3–55.5)
General fatigue (MFI) Median (IQR) 15 (10.3–18)
Figure 3.  Distribution of symptom severity.
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‘immune-enteroendocrine clusters’. In patients the latter cluster was associated to the phyla Firmicutes and Fuso-
bacteria, whereas the HC cluster showed no statistically significant association to microbiota at phylum level 
(Fig. 4 A and B).
Figure 4.  Integrative analysis on phylum level. (A) Overview, all correlations are plotted in relative correlation 
strength (disregarding statistical significance) to understand the relationships between the variables present 
in the given cohorts. Clusters of high intercorrelation are marked with a red circle. (B) Significance test: Only 
statistically significant correlations are plotted to estimate the generalizability of the patterns. Highlighted in 
color are the intercorrelation clusters. Clusters of high intercorrelation are marked with a red circle. Green 
edges show positive correlation, red edges negative correlation. Closer proximity of nodes and thicker 
edges show higher relative correlation strength. 1 = CLD1; 2 = DOUX2; 3 = PAR2; 4 = FFAR2; 5 = FFAR3; 
6 = IL10; 7 = IL8; 8 = OCLN; 9 = SCG2; 10 = SLC6A4; 11 = TJP1; 12 = TLR4; 13 = TNFα; 14 = MUC; 15 = NOX1; 
16 = TPH1; 17 = CHGA; 18 = CHGB; 19 = SCG3; 20 = TLR2; 21 = TLR6; 22 = TLR9; 23 = unclassified bacteria; 
24 = Actinobacteria; 25 = Bacteroidetes; 26 = Chlamydiae; 27 = Firmicutes; 28 = Fusobacteria; 29 = Lentisphaerae; 
30 = Proteobacteria; 31 = Tenericutes; 32 = Verrucomicrobia; 33 = Euryarchaeota.
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The permeability cluster uniquely found in patients contained occludin (OCLN) and tight junction protein 
1 (TJP1), both involved in epithelial barrier function, as well as the microbial recognition receptors Toll-like 
receptor 4 (TLR4) and protease activated receptor 2 (PAR2), which were all positively correlated to each other. 
The negative correlation of this cluster to the phyla Chlamydiae and Lentisphaerae was statistically significant 
(Fig. 4B).
In both IBS patients and HC, the immune-enteroendocrine cluster contained the Toll-like receptors TLR-
2, TLR-6 and TLR-9 and the chromogranins A and B as well as secretogranin 3, in HC additionally TLR-4. 
In patients this cluster was negatively correlated to mucosa-adherent Firmicutes, and positively correlated to 
Fusobacteria, whereas in HC no statistically significant association to any microbiota was confirmed (Fig. 4B).
Association between pattern of host‑microbiota interactions to symptoms. Two plots showing 
the between-layer relationship of key IBS symptoms (symptom layers) and the intercorrelation patterns of host-
microbiota interaction (mucosal layer) were created to highlight variables significantly associated to the clini-
cal phenotype of the IBS patients. The between-layer correlations predominantly demonstrated an association 
between psychological symptoms and the permeability cluster as well as the immune-enteroendocrine cluster, 
whereas gastrointestinal symptoms were directly associated to several microbiota and mucosal genes, and indi-
rectly connected to the clusters (Fig. 5 A and B). All significant correlations between symptoms and microbiota 
or host genes were of moderate strength ranging from ρ =|0.33| – |0.5|.
Associations between the GI symptom layer and the mucosal layer are featured in Fig. 5 A. Specifically, bloat-
ing showed a positive correlation to Lentisphaerae, as well as a negative correlation to Bacteroidetes; constipation 
was positively associated to Tenericutes as well as the anti-inflammatory cytokine IL-10; satiety showed a negative 
correlation to the tight junction protein TJP-1. However, abdominal pain and diarrhea showed no significant 
correlation to the analyzed host genes or microbiota.
The associations of both the mucosal layer and the GI symptom layer with the psychological symptoms layer 
are visualized in Fig. 5 B. General anxiety (HAD) was negatively correlated to Actinobacteria, and the tight-
junction proteins OCLN and TJP1, but showed no statistically significant direct correlation to the GI symptom 
layer. Depression was also negatively correlated to TJP1, and positively correlated to enteroendocrine protein 
CGB, and positively correlated to satiety. GI-specific anxiety (VSI) showed a negative correlation to Actinobac-
teria and a positive correlation to diarrhea. General fatigue (MFI) showed a positive correlation to CGB, and a 
negative correlation to TJP1, and was positively correlated to abdominal pain and satiety.
Detailed taxonomic assignment of patient‑specific interaction patterns on genus level. To 
better understand the above described associations, we performed additional network analyses with a more 
detailed taxonomic assignment on genus level (“desummarizing step”, as described in Fig. 2). This was done 
on the variables contained in the patients’ immune-enteroendocrine cluster as well as bacteria of the Firmi-
cutes-phylum, since after exclusion of outliers, Fusobacteria showed no statistically significant association. This 
showed that the genes of the immune-enteroendocrine cluster of patients were positively correlated to Fine-
goldia, Peptoniphilus, Ruminococcus II (of the family Lachnospiracea), Flavonifractor, Turicibacter and Acidami-
nococcus, and negatively correlated to Lactobacillus and Lactococcus (Fig. 6). All correlation coefficients are given 
in Supplementary Figure 5.
No further detailed analyses were conducted with regards to the permeability cluster in IBS patients since 
only the family Parachlamydiaceae of the Chlamydia phylum and only the genus Victivallis of the Lentisphaerae 
phylum were found to be present in the samples. Likewise, since the immune-activation cluster in HC showed 
no significant association to any microbiota, no detailed analyses were performed.
Additionally, genus-level network analyses were performed on Actinobacteria and Bacteroidetes, which were 
associated to symptoms but not mucosal genes. No further analyses were performed on the genera Tenericutes 
and Lentispharae, as for Tenericutes only Anaeroplasma and Asteroleplasma, and for Lentispharae only the genus 
Victivallis were found.
The Actinobacteria Microbacterium, Rothia, Bifidobacterium and Gardnerella, as well as unclassified genera 
from the families Bifidobacteriaceae and Coriobacteriaceae were associated to GI-specific and psychological 
symptoms (Supplementary Figure 3). All correlation coefficients are given in Supplementary Table 6.
The Bacteroidetes genera Barnesiella, Paraprevotella, Prevotella, Alistipes and Pedobacter as well as unclassified 
genera from the families Prevotellaceae and Flavobacteriaceae were negatively associated to both GI-specific 
and psychological symptoms (Supplementary Figure 3). All correlation coefficients are given in Supplementary 
Table 7.
Discussion
In this exploratory study we developed a stepwise integrative analysis pipeline tailored to identify host-microbiota 
interactions and link to symptoms. Furthermore, to demonstrate the execution, we applied the pipeline to a pilot 
data set. Here we identified patterns of host-microbiota interactions found in IBS patients but not in HC, and 
were able to link these patterns to IBS symptoms, thus confirming the usefulness of our approach. Intestinal 
bacteria may regulate intestinal epithelial barrier function and the immune response, and previous studies sup-
port the potential relevance of our findings. For example, Lactobacillus strains have been demonstrated to induce 
TLR2 signaling and impact tight junction proteins in epithelial  cells36. Further, L. plantarum has been shown to 
induce genomic DNA-dependent and TLR9-mediated elafin secretion in an epithelial cell  line37.
This study demonstrates a novel approach to explore and compare complex variable interrelatedness in both 
IBS patients and HC and to elucidate mucosal crosstalk between host and microbiota. This approach utilizes the 
correlation between variables to estimate potential interrelatedness. The resulting correlation patterns need to 
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Figure 5.  (A) Dual layer visualization of the association of host genes and mucosa-adherent microbiota with GI symptoms. 
The GI symptom layer reflects the relationship of the key IBS symptoms abdominal pain, constipation, diarrhea, satiety 
and bloating with each other, while the mucosal layer reflects patters of host-microbiota interaction corresponding to 
Fig. 3. Between-layer correlations are dotted and rho-value is given. (B) Triangle plot integrating three layers to show 
the inter-layer associations between patterns of host-microbiota interaction, GI symptoms and psychological symptoms. 
Between-layer correlations are dotted and rho-value is given. Only statistically significant correlations are plotted. Green 
edges show positive correlation, red edges negative correlation. Closer proximity of nodes and thicker edges show higher 
relative correlation strength in the two layers, which is disregarded in the between-layer edges. 1 = CLD1; 2 = DOUX2; 
3 = PAR2; 4 = FFAR2; 5 = FFAR3; 6 = IL10; 7 = IL8; 8 = OCLN; 9 = SCG2; 10 = SLC6A4; 11 = TJP1; 12 = TLR4; 13 = TNFα; 
14 = MUC; 15 = NOX1; 16 = TPH1; 17 = CHGA; 18 = CHGB; 19 = SCG3; 20 = TLR2; 21 = TLR6; 22 = TLR9; 23 = unclassified 
bacteria; 24 = Actinobacteria; 25 = Bacteroidetes; 26 = Chlamydiae; 27 = Firmicutes; 28 = Fusobacteria; 29 = Lentisphaerae; 
30 = Proteobacteria; 31 = Tenericutes; 32 = Verrucomicrobia; 33 = Euryarchaeota.
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be interpreted with caution, but may nevertheless highlight variables which might be functionally connected, 
either directly or indirectly by mediators. Therefore, using correlations as an approximation for the potential 
functional connection of variables may aid in the development of novel hypotheses regarding IBS pathophysiol-
ogy and symptom generation, and suggest relevant targets for further experimental exploration. The differences 
of correlation patters of host-microbiota interaction found between IBS patients and HC, and the association 
of these to key IBS symptoms, validate the suitability of our stepwise integrative analysis pipeline to analyze 
complex, multilevel datasets and define which variable/s may be of most relevance. The multilayer graphs pro-
vide further insight and enhance interpretability of variable association and the role of potential mediators in 
complex diseases such as IBS.
Importantly, we demonstrated some patterns to be common for both IBS patients and HC, whereas oth-
ers were specific for patients. Potentially, patient-specific patterns are related to disease mechanisms and may 
improve understanding underlying pathology. In addition, the visualization strategy presented here can be scaled 
to include additional compartments, thus facilitating the reduction of the amount of latent variables and increas-
ing the resolution of potential pathomechanistic insights. Thus, the integrative analysis pipeline developed and 
presented in this study can provide additional information that traditional univariate analyses do not reveal, 
making this method useful for research questions relevant to the field of multifactorial diseases.
A method that aids in identifying relevant variables in a highly complex dataset is especially relevant for 
improving our understanding of the details of host-microbiota interactions. The majority of gut microbiota 
species are difficult and time-consuming to culture, limiting our experimentally validated knowledge of the 
physiological function of these species. Integrative analyses as demonstrated here may therefore be highly useful 
to identify which of these microbial species are most relevant to focus on experimentally, improving the cost-
effectiveness of such studies and likelihood of relevant findings.
Figure 6.  Detailed analysis of the immune-enteroendocrine cluster in IBS patients and microbiota on genus 
level. Red color highlights the bacteria significantly associated to mucosal markers, while grey marks remaining 
bacteria of the phylum. Only statistically significant correlations are plotted. Green edges show positive 
correlation, red edges negative correlation. Closer proximity of nodes and thicker edges show higher relative 
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In this study we have preceded the network analysis with a screening for multivariate outliers. This was done 
for two reasons: The in between sample variability expected in microbiota analyses as well as the heterogeneity 
typically observed in IBS  cohorts9,38. A few microbial genera were only present in singular individuals, the cause 
of which is yet unidentified. Given the relatively low number of subjects included and the exploratory nature 
of this study, excluding these outliers likely is the best compromise to reduce spurious results while maximiz-
ing statistical power. In studies including a higher amount of study subjects this problem may additionally be 
addressed by applying a cut-off that excludes microbial genes that are present only in very low frequencies or 
only in a very low number of individuals, thus further reducing technical and biological noise in the dataset.
A major challenge in integrative analyses is the question of how to quantify the association between variables 
given highly diverse data characteristics. Rank correlations, as applied in this study, enable the simultaneous 
analysis of data of different scales. As mentioned above, correlations need to be interpreted with caution. In 
biological systems functionally connected mechanisms are commonly correlated, but, given the complexity of 
biological systems, direct causality cannot be concluded. Nevertheless, this integrative analytical approach can 
be applied to narrow down which components of complex biological systems may most likely be functionally 
connected and therefore are most relevant targets for more detailed experimental analyses. Furthermore, by 
applying a multilayer approach to the research question, the role of potential mediators is visualized and can be 
taken into account when interpreting the plots. Additional layers can be added to the analysis in future studies 
to further enhance the complexity of the obtained results.
Our stepwise integrative analysis pipeline comprises several steps, which, in combination, narrow down the 
most relevant variables. The initial step is a summarizing/clustering step, which favors the interpretability of the 
resulting integrative plot, but sacrifices detailed information. Therefor complementary secondary integrative 
plots are created to achieve a higher resolution of variable associations. Choosing the right strategy for creating 
the initial summarized variables remains a challenge since very little is known about most gut microbial species. 
With growing knowledge about the physiological function of these species a better summarizing criterion than 
phylogenetic relatedness may be developed, but at this time point this likely is the best alternative. Despite these 
considerations, our approach showed very noteworthy results in the presented study, suggesting that future 
studies, with further improved summarizing step to reduce the risk of false-negative findings, may yield even 
more accurate results.
There are several limitations to this study. First, the rather small number of mucosal genes analyzed in this 
study is a limitation, as genes not analyzed in this study will most likely also be of high relevance in the orchestra-
tion of host-microbiota interaction. Hence, using comprehensive methods such as whole transcriptome shotgun 
sequencing to obtain a more extensive dataset of host gene expression would make a more detailed and accurate 
identification of potential key players possible. Second, while 16 s sequencing is state-of-the-art in microbial 
research and useful in identifying the microbial composition in obtained  samples39, it does not provide infor-
mation of quantitative nature. Third, traditionally OTU counts are normalized to account for sequencing depth 
using ratio-calculations or  rarefication40. These methods have been criticized, and currently various improved 
methods are developed, tested and  discussed40–42. We have thus chosen to apply the median of ratios method as 
implemented in  DESeq233, which has shown to produce more reliable results when normalizing count data than 
traditional  methods40,42. Fourth, our patients were recruited from a secondary/tertiary care unit, which holds 
the risk of a recruitment bias leading to higher severity of symptoms. Fifth, the microbiota data was sequenced 
using only the V5-V6 regions, limiting the resolution of this data, which may be the reason a number of bacteria 
remained unclassified. Still, this approach has so far been one of the most used methods to analyze gut micro-
biota. Despite these limitations, we were able to show noteworthy differences between well phenotyped IBS 
patients of all subtypes and HC and identify distinct associations between host genes and microbiota, support-
ing the generalizability of our findings. The extensive phenotyping conducted on our participants allows us to 
assume a low degree of biological noise in our dataset, which is a strong argument for the relevance of our results.
Taken together, we have developed a novel strategy tailored for analyzing the complex host-microbiota inter-
action and its association to symptoms and demonstrated its successful application to a pilot study dataset. Dis-
tinct differences between IBS patients and HC were identified, and an association of host-microbiota interaction 
patterns to key IBS symptoms was demonstrated, as well as the potential role of mediators highlighted. Applying 
the described pipeline to even more comprehensive datasets may aid in unravelling the complex host-microbiota 
interactions in health and disease and aid in identifying key pathophysiological mechanisms and potential bio-
markers. The approach can be used to screen various complex datasets and identify the most relevant variables 
for further experimental validation.
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